Glixogen Therapeutics
Treatment for Enhancing Remyelination in Neurodegenerative Disorders
Company Overview
Snapshot
Founded in October 2018 by Dr. Yair Fisher and Prof. James Salzer, Glixogen Therapeutics operates with 1–10 employees. The company secured its seed funding round in January 2019, with participation from FutuRx.
Business overview
Glixogen Therapeutics is a biopharmaceutical company focused on developing treatments for neurodegenerative disorders, specifically those characterized by damage to the neuron's myelin sheath, such as multiple sclerosis (MS). The company's core technology involves selective small molecule inhibitors targeting the transcription factor Gli1, aiming to facilitate neuronal remyelination and modify disease outcomes. Operating within the Health Tech & Life Sciences sector, Glixogen Therapeutics is active in drug discovery and development, targeting the pharmaceutical market.
Strategic signal
In January 2019, Glixogen Therapeutics was launched by FutuRx to develop novel therapies for multiple sclerosis and other demyelinating disorders. This launch signals strategic validation for the company's approach to addressing significant unmet medical needs in neurodegenerative diseases, indicating early investor confidence in its research and development pipeline.
Log in to access full profile ›Company Intelligence Q&A
- What is Glixogen Therapeutics' primary focus?
- Glixogen Therapeutics is focused on developing treatments to enhance remyelination in neurodegenerative disorders, particularly those driven by damage to the neuron's myelin sheath, such as multiple sclerosis (MS).
- When was Glixogen Therapeutics founded?
- Glixogen Therapeutics was founded in October 2018.
- Who are the founders of Glixogen Therapeutics?
- Glixogen Therapeutics was founded by Dr. Yair Fisher and Prof. James Salzer.
- What was a key early development for Glixogen Therapeutics?
- In January 2019, FutuRx launched Glixogen Therapeutics to develop novel therapies for multiple sclerosis and other demyelinating disorders.
- What is the company's status as of December 2024?
- Glixogen Therapeutics ceased to operate in December 2024.